United States Patent for Klaria’s Sumatriptan Alginate Film has been issued, patent protection is extended until 2038

Klaria announces today that the Alginate Film Combination Patent for Sumatriptan has been issued in the United States.  The patent protection for Sumatriptan Alginate Film will now last until 2038.  The patent will be issued under patent number 11007144.

Klaria’s intellectual property (IP) strategy is to file “Alginate Film Combination Patents” for all programs in the company’s development pipeline.  These patents protect innovations related to the combination of the pharmaceutical and the polymers in the Alginate Film.  The goal is to extend the lifetime of market exclusivity and to increase the strength of the patent protection. 

The Sumatriptan Alginate Film Combination Patent has now been granted by the United States Patent Office (USPTO).  This marks the second time that the USPTO approves an “Alginate Film Combination Patent”.

Jesper Wiklund, CEO of Klaria said “This shows that our IP strategy is effective in the world’s most valuable market for pharmaceuticals, the United States.  Most importantly, this significantly increases the value of our Sumatriptan Alginate Film program.  Moreover, it increases the probability that other Alginate Film Combination Patents will be granted in the US in the future.”

About KL-00119:  KL-00119 is an alginate-based oral trans-mucosal film.  KL-00119 is the first oral trans-mucosal migraine product and is designed to be a significant improvement to all available acute migraine treatments available to patients today, particularly in patients suffering from migraine-induced nausea and vomiting.   KL-00119 is also particularly suited for the treatment of migraine in pediatric populations.   KL-00119 is a unique molecular dispersion of the active antimigraine drug sumatriptan.  The KL-00119 film presents sumatriptan to the oral mucosal surface in a unique way to allow rapid, consistent absorption with the lowest possible burden on the patient.  The base film-forming alginate and the sumatriptan-containing films have been the subject of comprehensive intellectual property protection, thus ensuring prolonged market exclusivity.  The uniqueness and promise of the KL-00119 has been confirmed by the project being awarded the exclusive European Commission Horizon 2020 Innovation Grant in 2018 (Grant Number 8296159). 

Download as PDF